Celltrion (KRX:068270) posted first-half 2026 revenue growth of 18% year-over-year despite a 15% decline in consolidated revenue, as contract manufacturing volumes from third-party clients offset a cyclical slowdown in its own biosimilar product sales.
Celltrion (KRX:068270) biosimilar Stekla, a copy of Janssen's ustekinumab for autoimmune disease, held 16.2% of the US market by volume in July 2026, up from 14.9% in June, data-tracking firm IQVIA reported Wednesday.
Celltrion's biosimilar Stekima has captured 16.2% market share in the US ustekinumab category as of July 2026.
Celltrion (068270) said in a regulatory filing Monday that its board approved buying back up to 524,384 common shares, worth as much as ₩100.0bn (~$72.6m), with purchases running from September 1 through November 30.
| Symbol | Last Price |
|---|---|
| 207940Samsung Biologics Co., Ltd. | ₩1,447,000 -2.0% |
| 196170Alteogen Inc. | ₩288,500 +1.9% |
| 326030SK biopharmaceuticals Co., Ltd. | ₩86,600 +0.2% |
| 128940Hanmi Pharm. Co., Ltd. | ₩473,500 +2.8% |
| 000100Yuhan Corporation | ₩81,400 +0.0% |
| 028300HLB Co., Ltd. | ₩33,750 +2.9% |
| 298380ABL Bio Inc. | ₩71,400 +5.6% |
| 000250Samchundang Pharm | ₩157,000 +1.0% |
| 087010Peptron, Inc. | ₩157,300 +7.3% |
| 141080LigaChem Biosciences Inc. | ₩92,000 +4.2% |